Warning: The NCBI web site requires JavaScript to function. more...
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.
Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, Culler SD.
Cost Eff Resour Alloc. 2009 Apr 7;7:4.
Related citations
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.
Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.
Pharmacoeconomics. 2005;23 Suppl 1:75-89.
Cost-effectiveness of several atypical anti-psychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD.
J Med Econ. 2012 Feb 3. [Epub ahead of print]
Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.
Pharmacoeconomics. 2005;23(3):299-314.
Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.
Pharmacoeconomics. 2008;26(4):341-58.
One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.
Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.
Curr Med Res Opin. 2008 Dec;24(12):3341-55. Review.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M, Okamoto MP.
J Eval Clin Pract. 2007 Jun;13(3):453-60.
A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.
Beard SM, Maciver F, Clouth J, Rüther E.
Eur J Health Econ. 2006 Sep;7(3):165-72.
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.
Pharmacoeconomics. 2005;23 Suppl 1:35-47.
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Laux G, Heeg B, van Hout BA, Mehnert A.
Pharmacoeconomics. 2005;23 Suppl 1:49-61.
Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Foster RH, Goa KL.
Pharmacoeconomics. 1999 Jun;15(6):611-40. Review.
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP.
J Manag Care Pharm. 2010 Apr;16(3):217-30. Review.
Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.
Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D.
Value Health. 2012 Jan;15(1):55-64. Epub 2011 Nov 12.
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
Kirbach S, Simpson K, Nietert PJ, Mintzer J.
Clin Drug Investig. 2008;28(5):291-303.
The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.
Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR.
J Manag Care Pharm. 2006 May;12(4):322-30.
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP.
Pharmacoeconomics. 2004;22(6):389-411. Review.
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Bobes J, Cañas F, Rejas J, Mackell J.
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1287-97.
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.
BMC Psychiatry. 2008 Apr 4;8:19.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on